Overview
Status
Active
Registry date
2017-12-08
Share capital
5,000.00 PLN
Registered address
ul. Ludwika Waryńskiego 3A, 00-645 Warszawa, Poland
Electronic delivery address
AE:PL-71346-32324-EDFEG-12
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 154 days late).
- 202514/05/2026
- 202410/06/2025
- 202304/06/2024
- 202209/06/2023
- 202116/12/2022
- 202004/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 5.75mMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD 278.12kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 5.34mMedianUSD 873.06kAverageUSD 21.43m
Assets
This companyUSD 2.69mMedianUSD 897.46kAverageUSD 31.52m
Industry
Authorized Representatives
Ulrich Stefan Lentzer – Management Board Member
Marek Michał Macyszyn – Attorney-in-fact (sole)
Omar White – Management Board Member
Prasanna Thombre – Management Board Member
Trent Townsend – Management Board Member
Manner of representation
Each member of the management board is entitled to independently represent the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Vertex Pharmaceuticals (europe) Limited | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-02-08.
73 1030 1508 0000 0008 1878 4000
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2020-03-12 | Address change (Ul. Emilii Plater 53, 00-113, Warszawa → Ul. Ludwika Waryńskiego 3a, 00-645, Warszawa) | |
| 2017-12-08 | Entered in the register |
FAQ
The main business activity of Vertex Pharmaceuticals (Poland) focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on December 8, 2017.
The headquarters is located at: ul. Ludwika Waryńskiego 3A, 00-645 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of $5,749,858 in 2025, which is an increase of 1.2% compared to 2024.
Yes, the company recorded a net profit of $278,116 in 2025, meaning the company decreased its profit by 29.5%.
The largest operating cost category falls under employee remuneration. This category amounted to $2,044,627 in 2025, representing 38% of all operating expenses.
Last updated: 2026-10-07